MATERIAL FACT

BIOTOSCANA INVESTMENTS S.A. («Company» or «GBT») (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general the acquisition of Laboratorio DOSA S.A., a specialty pharmaceutical manufacturer based in Argentina. The transaction continues to advance GBT´s strategic agenda and expands GBT´s scope into the promising area of severe lung diseases. The bulk of DOSA´s products treat severe pulmonary pathologies including idiopathic pulmonary fibrosis and cystic fibrosis and it has additional portfolios in oncology, hematology and HIV. Laboratorio DOSA posted revenues of ARS 326M (approx. BRl 61M) in 2016, up from ARS 228M (approx. BRL 42M) in 2015.

The operation was closed at a price of USD 29.9M (approx. BRL 100M), of which USD 20.7M were paid in cash, USD 5M were deposited in an escrow account which will be freed in 2022 and USD 4.2M which will be paid in annual payments along the following 4 years.

The company will provide more information regarding the acquisition on the conference call for the 3Q17 results on November 14th.

Montevideo, November 13, 2017

BIOTOSCANA INVESTMENTS S.A.
Claudio Coracini
Legal representative in Brazil

To access the PDF version, please click here.